{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:10:25Z","timestamp":1784815825866,"version":"3.55.0"},"reference-count":35,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,4,28]]},"DOI":"10.2967\/jnumed.125.270944","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:50:20Z","timestamp":1784814620000},"page":"jnumed.125.270944","source":"Crossref","is-referenced-by-count":0,"title":["Outcome Prediction After [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA I&amp;T in Metastatic Castration-Resistant Prostate Cancer: External Validation of a [\n                    <sup>68<\/sup>\n                    Ga]Ga-PSMA-11 PET\u2013Based Model with [\n                    <sup>18<\/sup>\n                    F]F-Flotufolastat"],"prefix":"10.2967","author":[{"given":"Amir","family":"Karimzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"F\u00fctterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6m\u00fcr","family":"Coban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Nekolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026072306500902000_jnumed.125.270944v1.1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.173757"},{"key":"2026072306500902000_jnumed.125.270944v1.2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol."},{"key":"2026072306500902000_jnumed.125.270944v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2026072306500902000_jnumed.125.270944v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026072306500902000_jnumed.125.270944v1.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026072306500902000_jnumed.125.270944v1.6","doi-asserted-by":"crossref","first-page":"1483953","DOI":"10.3389\/fonc.2024.1483953","article-title":"Initial clinical experience with 177Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial","volume":"14","author":"Hansen","year":"2024","journal-title":"Front Oncol."},{"key":"2026072306500902000_jnumed.125.270944v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00274-6"},{"key":"2026072306500902000_jnumed.125.270944v1.8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.37894","article-title":"18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging","volume":"10","author":"Werner","year":"2020","journal-title":"Theranostics."},{"key":"2026072306500902000_jnumed.125.270944v1.9","unstructured":"Highlights of prescribing information: POSLUMA (flotufolastat F 18) injection. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216023s000lbl.pdf. Accessed May 12, 2026."},{"key":"2026072306500902000_jnumed.125.270944v1.10","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00259-024-07003-2","article-title":"Prognostic 18F-flotufolastat PET parameters for outcome assessment of 177Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer","volume":"52","author":"Karimzadeh","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026072306500902000_jnumed.125.270944v1.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265346"},{"key":"2026072306500902000_jnumed.125.270944v1.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234922"},{"key":"2026072306500902000_jnumed.125.270944v1.13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40658-019-0257-8","article-title":"Quantitative implications of the updated EARL 2019 PET-CT performance standards","volume":"6","author":"Kaalep","year":"2019","journal-title":"EJNMMI Phys."},{"key":"2026072306500902000_jnumed.125.270944v1.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2026072306500902000_jnumed.125.270944v1.15","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00259-021-05497-8","article-title":"Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting","volume":"49","author":"Johnsson","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026072306500902000_jnumed.125.270944v1.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.261863"},{"key":"2026072306500902000_jnumed.125.270944v1.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.198119"},{"key":"2026072306500902000_jnumed.125.270944v1.18","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6787"},{"key":"2026072306500902000_jnumed.125.270944v1.19","unstructured":"Ltman DG . Practical Statistics for Medical Research. 1st ed. Chapman and Hall\/CRC; 1990: 367\u2013371."},{"key":"2026072306500902000_jnumed.125.270944v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"2026072306500902000_jnumed.125.270944v1.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1982.03320430047030"},{"key":"2026072306500902000_jnumed.125.270944v1.22","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780030207"},{"key":"2026072306500902000_jnumed.125.270944v1.23","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2022."},{"key":"2026072306500902000_jnumed.125.270944v1.24","doi-asserted-by":"crossref","first-page":"102862","DOI":"10.1016\/j.eclinm.2024.102862","article-title":"Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial","volume":"77","author":"Herrmann","year":"2024","journal-title":"EClinicalMedicine."},{"key":"2026072306500902000_jnumed.125.270944v1.25","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.3390\/cancers15204907","article-title":"Prognostic value of the De Ritis ratio for overall survival in patients with metastatic castration-resistant prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy","volume":"15","author":"Gaal","year":"2023","journal-title":"Cancers (Basel)."},{"key":"2026072306500902000_jnumed.125.270944v1.26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.62347\/INCG3525","article-title":"Normal-organ distribution of PSMA-targeting PET radiopharmaceutical 18F-flotufolastat: a post hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies","volume":"14","author":"Penny","year":"2024","journal-title":"Am J Nucl Med Mol Imaging."},{"key":"2026072306500902000_jnumed.125.270944v1.27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution","volume":"19","author":"Ferreira","year":"2019","journal-title":"Cancer Imaging."},{"key":"2026072306500902000_jnumed.125.270944v1.28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13550-024-01190-7","article-title":"Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy","volume":"15","author":"Heilinger","year":"2025","journal-title":"EJNMMI Res."},{"key":"2026072306500902000_jnumed.125.270944v1.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262713"},{"key":"2026072306500902000_jnumed.125.270944v1.30","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","article-title":"SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T","volume":"50","author":"Hartrampf","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026072306500902000_jnumed.125.270944v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00605-2"},{"key":"2026072306500902000_jnumed.125.270944v1.32","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460"},{"key":"2026072306500902000_jnumed.125.270944v1.33","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S1470-2045(25)00339-0","article-title":"Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol."},{"key":"2026072306500902000_jnumed.125.270944v1.34","doi-asserted-by":"crossref","first-page":"e222148","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology."},{"key":"2026072306500902000_jnumed.125.270944v1.35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267723"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:50:22Z","timestamp":1784814622000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":35,"alternative-id":["10.2967\/jnumed.125.270944"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270944","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}